GLP1R and diabetic kidney disease: Specifically, the sodium-glucose co-transporter type 2 inhibitors (SGLT2i) and finerenone are indicated for the treatment of diabetic nephropathy; furthermore, GLP-1 receptor agonists have an interesting nephroprotective effect in diabetic nephropathy, though this might be mediated by their strong effect on weight loss, which may pose a difficulty in interpreting the effects and will be a matter of future analysis.